$ cat ./records/gates-foundation-funds-path-to-accelerate-japanese-encephalitis-v-2011.txt
Gates Foundation Funds PATH to Accelerate Japanese Encephalitis Vaccine Introduction in High-Burden Regions
[RECORD.TXT] · cat --full
The Gates Foundation funded PATH to support the introduction of SA 14-14-2 live attenuated Japanese encephalitis (JE) vaccine across high-burden regions of South and Southeast Asia. JE causes 68,000 cases and 17,000 deaths annually, with no approved treatment. PATH's Gates-funded programme provided immunisation programme assessments, cold-chain evaluations, and advocacy support that accelerated national JE vaccine introductions in Nepal, India, Cambodia, and Laos, and built the evidence base for WHO's prequalification of the SA 14-14-2 vaccine.
Source: https://www.path.org/our-impact/case-studies/vaccine-japanese-encephalitis/
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
ROTAVAC — Gates-Supported $1 Oral Rotavirus Vaccine Reaches 25 Million Indian Children Annually
Next →
Gates Foundation Partnership Reduces Rotavirus Vaccine Cost from $200 to $1 Per Dose
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.